Influence of bacteriophage preparations on migration of HL-60 leukemia cells In Vitro

Anticancer Research

Volumn 33, Issue 4, 2013, Pages 1569-1574

  Kurzepa Skaradzinska, Aneta ^a,b   Skaradzinski, Grzegorz ^a   Weber Dabrowska, Beata ^a   Zaczek, Maciej ^a   Maj, Tomasz ^a   Slawek, Anna ^a   Switalska, Marta ^a   Maciejewska, Magdalena ^a   Wietrzyk, Joanna ^a   Rymowicz, Waldemar ^b   Gorski, Andrzej ^a,c  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROC AW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Bacteriophages; HL 60; Leukemia; Phage therapy; Phage cancer interactions; Phage mammalian interactions

Indexed keywords

LIPOPOLYSACCHARIDE;

ARTICLE; BACTERIOPHAGE; CELL MIGRATION; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

BACTERIOPHAGES; CELL MOVEMENT; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HL-60 CELLS; HUMANS; LIPOPOLYSACCHARIDES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84876771024     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Deresinski S: Bcteriophage therapy: Exploiting smaller fleas. Clin Infect Dis 48: 1096-1101, 2009.
2. Housby JN and Mann NH: Phage therapy. Drug Discov Today 14: 536-540, 2009.
3. Kutateladze M and Adamia R: Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 28: 591-595, 2010.
4. Burrowes B, Harper DR, Anderson J, McConville M and Enright MC: Bacteriophage therapy: Potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti Infect Ther 9: 775-785, 2011.
5. Kumari S, Harjai K and Chhibber S: Evidence to support the therapeutic potential of bacteriophage Kpn5 in burn wound infection caused by Klebsiella pneumoniae in BALB/c mice. J Microbiol Biotechnol 20: 935-941, 2010.
6. Sunagar R, Patil SA and Chandrakanth RK: Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice. Res Microbiol 161: 854-860, 2010.
7. Connerton PL, Timms AR and Connerton IF: Campylobacter bacteriophages and bacteriophage therapy. J Appl Microbiol 111: 255-265, 2011.
8. Khawaldeh A, Morales S, Dillon B, Alavidze Z, Ginn AN, Thomas L, Chapman SJ, Dublanchet A, Smithyman A and Iredell JR: Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J Med Microbiol 60: 1697-1700, 2011.
9. Kumari S, Harjai K and Chhibber S: Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae 5055. J Med Microbiol 60: 205-210, 2011.
10. Lim TH, Lee DH, Lee YN, Park JK, Youn HN, Kim MS, Lee HJ, Yang SY, Cho YW, Lee JB, Park SY, Choi IS and Song CS: Efficiacy of bacteriophage therapy on horizontal transmission of Salmonella gallinarum in commercial layer chickens. Avian Dis 55: 435-438, 2011.
11. Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Ahanahan F, Coffey A, Ross RP and Hill C: Bacteriophages MR299-2 and NH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 3: e00029-12, 2012.
12. Pouillot F, Chomton M, Blois H, Courroux C, Noelig J, Bidet P, Bingen E and Bonacorsi S: Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b: H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother 56: 3568-3575, 2012.
13. Lin NT, Chiou PY, Chang KC, Chen LK and Lai MJ: Isolation and characterization of AB2: A novel bacteriophage of Acinetobacter baumannii. Res Microbiol 161: 308-314, 2010.
14. Gupta R and Prasad Y: Efficacy of polyvalent bacteriophage P-27/HP to control multidrug-resistant Staphylococcus aureus associated with human infections. Curr Microbiol 62: 255-260, 2011.
15. Hsieh SE, Lo HH, Chen ST, Lee MC and Tseng YH: Wide host range and strong lytic activity of Staphylococcus aureus lytic phage Stau2. Appl Environ Microbiol 77: 756-761, 2011.
16. Morello E, Saussereau E, Maura D, Huerre M, Touqui L and Debarbieux L: Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: First steps towards treatment and prevention. PLoS One 6: e16963, 2011.
17. Vinodkumar CS, Srinivasa H, Basavarajappa KG, Geethalakshmi S and Bandekar N: Isolation of bacteriophages to multidrug-resistant Enterococci obtained from diabetic foot: A novel antimicrobial agent waiting on the shelf. Indian J Pathol Microbiol 54: 90-95, 2011.
18. Loc-Carrillo C and Abedon ST: Pros and cons of phage therapy. Bacteriophage 1: 111-114, 2011.
19. Gilmore BF: Bacteriophages as anti-infective agents: Recent developments and regulatory challenges. Expert Rev Anti Infect Ther 10: 533-535, 2012.
20. Abedon ST, Kuhl SJ, Blasdel BG and Kutter EM: Phage treatment of human infections. Bacteriophage 1: 66-85, 2011.
21. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S and Abedon ST: Phage therapy in clinical practice: Treatment of human infections. Curr Pharm Biotechnol 11: 69-86, 2010.
22. Ryan EM, Gorman SP, Donnelly RF and Gilmore BF: Recent advantages in bacteriophage therapy: How delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol 63: 1253-1264, 2011.
23. Chan BK and Abedon ST: Phage therapy and pharmacology phage cocktails. Adv Appl Microbiol 78: 1-23, 2012.
24. Gu, J, Liu X, Li Y, Han W, Lei L, Yang Y, Zhao H, Gao Y, Song J, Lu R, Sun C and Feng X: A method for generation phage cocktail with great therapeutic potential. PLoS One 7: e31698, 2012.
25. Hyman P and Abedon ST: Bacteriophage host range and bacterial resistance. Adv Appl Microbiol 70: 217-248, 2010.
26. Kivi S, Peltomäki T, Luomala K and Sarimo SS: Some properties of Streptococcus thermophiles bacteriophages. Folia Microbiol (Praha) 32: 101-106, 1987. (Pubitemid 17039629)
27. Kucharewicz-Krukowska A and Slopek S: Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch Immunol Ther Exp 35: 553-561, 1987.
28. Huff WE, Huff GR, Rath NC and Donoghue AM: Immune interference of bacteriophage efficacy when treating colibacillosis in poultry. Poult Sci 89: 895-900, 2010.
29. Weber-Dabrowska B, Dabrowski M and Slopek, S: Studies on bacteriophage penetration in patients subjected to phage therapy. Arch Immunol Ther Exp 35: 563-568, 1987.
30. Weber-Dabrowska B, Zimecki M and Mulczyk M: Effective phage therapy is associated with normalization of cytokine production by blood cell cultures. Arch Immunol Ther Exp 48: 31-38, 2000.
31. Kantoch, M: Studies on phagocytosis of bacterial viruses I. Arch Immun Ther Exp 6: 63, 1958a.
32. Kantoch M: Studies on phagocytosis of bacterial viruses II. Arch Immun Ther Exp 6: 417, 1958b.
33. Kantoch M, Skurski A and Wieczorek Z: In vitro blockade of bacterial phagocytosis by means of bacterial viruses. Schweiz Z Pathol Bacteriol 21: 1106-1119, 1958.
34. Gorski A, Dabrowska K, Switala-Jelan K, Nowaczyk M, Weber-Dabrowska B, Boratynski J, Wietrzyk J and Opolski A: New insights into the possible role of bacteriophages in host defense and disease. Med Immunol 2: 2, 2003.
35. Gorski A, Wazna E, Weber-Dabrowska B, Dabrowska K, Switala-Jelen K, and Miedzybrodzki R: Bacteriophage translocation. FEMS Immunol Med Microbiol 46: 313-319, 2006.
36. Gorski A, Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Lobocka M, Fortuna W, Letkiewicz S, Zimecki M and Filby G: Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs 10: 766-774, 2009.
37. Gorski A, Miedzybrodzki R, Borysowski J, Dabrowska K, Wierzbicki P, Ohams M, Korczak-Kowalska G, Olszowska-Zaremba N, Lusiak-Szelachowska M, Klak M, Jonczyk E, Kaniuga E, Golas A, Purchla S, Weber-Dabrowska B, Letkiewicz S, Fortuna W, Szufnarowski K, Pawelczyk Z, Rogoz P and Klosowska D: Phage as a modulator of immune response: Practical implications for phage therapy. Adv Virus Res 83: 41-71, 2012.
38. Kniotek, M, Ahmed AMA, Dabrowska K, Switala-Jelen K, Opolski A and Gorski A: Bacteriophage interactions with T-cells and platelets. In: Cytokine Network, Regulatory Cells, Signaling, and Apoptosis (Immunology). E. Skamene (ed.). Bologna, pp. 189, 2004.
39. Przerwa A, Zimecki M, Switala-Jelen K, Dabrowska K, Krawczyk E, Luczak M, Weber-Dabrowska B, Syper D, Miedzybrodzki, R and Gorski A: Effects of bacteriophages on free radical production and phagocytic functions. Med Microbiol Immunol 195: 143-150, 2006. (Pubitemid 44421174)
40. Miedzybrodzki R, Switala-Jelen K, Fortuna W, Weber-Dabrowska B, Przerwa A, Lusiak-Szelachowska M, Dabrowska K, Kurzepa A, Boratynski J, Syper D, Pozniak G, Lugowski C and Gorski A: Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. Virus Res 131: 233-242, 2008. (Pubitemid 351173394)
41. Bloch H: Experimental investigation on the relationships between bacteriophages and malignant tumors. Arch Virol 1: 481-496, 1940.
42. Kantoch M and Mordarski M: Binding of bacterial viruses by tumor cells in vitro. Postepy Hig Med Dosw 12: 191-192, 1958 (in Polish).
43. Dabrowska K, Skaradzinski G, Kurzepa A, Wietrzyk J, Jonczyk P, Owczarek B, Zaczek M, Switala-Jelen K, Pozniak G, Weber-Dabrowska B and Gorski A: The effect of bacteriophages T4 and HAP1 on in vitro melanoma migration. BMC Microbiol 9: 13, 2009.
44. Szczaurska-Nowak K, Dabrowska K, Celka M, Kurzepa A, Nevozhay D, Wietrzyk J, Switala-Jelen K, Syper D, Pozniak G, Opolski A, Gorski A and Radzikowski C: Antitumor effect of combined treatment of mice with cytostatic agents and bacteriophage T4. Anticancer Res 29: 2361-2370, 2009.
45. Dabrowska K, Opolski A, Wietrzyk J, Switala-Jelen K, Godlewska J, Boratynski J, Syper D, Weber-Dabrowska B and Gorski A: Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. Anticancer Res 24: 3991-3995, 2004. (Pubitemid 40468698)
46. Kochetkova VA, Mamontov AS, Moskovtseva RL, Erastova EI, Trofimov EI, Popov MI and Dzhubalieva SK: Phagotherapy of postoperative suppurative- inflamatory complications in patients with neoplasms. Sov Med 6: 23-26, 1989.
47. Tolkacheva, TV, Abakumov EM, Martynova VA and Golosova TV: Correction of intestinal dysbacteriosis with biological preparations in acute leukemia. Probl Gematol Pereliv Krovi 26: 29-33, 1981 (in Russian). (Pubitemid 11028482)
48. Carlson K and Miller ES: Working with T4. In: Molecular Biology of Bacteriophage T4. Karam JD (ed.). Washington DC, American Society for Microbiology Press, pp. 421-426, 1994.
49. Boratynski J, Syper D, Weber-Dabrowska B, Lusiak-Szelachowska M, Pozniak G and Gorski A: Preparation of endotoxin-free bacteriophages. Cell Mol Biol Lett 9: 253-259, 2004. (Pubitemid 38902220)
50. Adams MH: Enumeration of bacteriophage particles. In: The Bacteriophages. Interscience Publ, New York, 1959.
51. Westphal OJK: Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure. Meth Carbohydr Chem 5: 83-89, 1965.
52. Dowdy S, Weardon S and Chilko D: Statistics for Research. Wiley Interscience: New Jersey, USA, 2004.
53. Przerwa A, Kniotek M, Weber - Daborwska B, Switala - Jelen K, Dabrowska K and Gorski A: Bacteriophages inhibit Il-2 production by human lymphocytes. Congress of European Society of Organ Transplantation, 15-19.10 2005, Geneva, Switzerland, 2005.
54. Dabrowska K, Opolski A, Wietrzyk J, Switala-Jelen K, Boratynski J, Nasulewicz A, Lipinska L, Chybicka A, Kujawa M, Zabel M, Dolinska-Krajewska B, Piasecki E, Weber-Dabrowska B, Rybka J, Salwa J, Wojdat E, Nowaczyk M and Gorski A: Antitumor activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of beta3 integrin signaling pathway. Acta Virol 48: 241-248, 2004. (Pubitemid 47434295)